In its recent financial results, Basilea's partner Astellas reported Cresemba (isavuconazole, antifungal) Q2/2019 US sales of $37m, taking H1/2019 US sales to $67m (+26% YoY), slightly above our $65.5m forecast. The company also stated that it projects FY2019E (April 2019 - March 2020) sales to reach $143m, in line with our estimate for Astellas's fiscal year. This increases our confidence in our peak sales forecasts for Cresemba of nearly $230m in the US and $645m globally by 2026E, of which
01 Aug 2019
Astellas reports robust Cresemba sales
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Astellas reports robust Cresemba sales
Basilea Pharmaceutica AG (0QNA:LON) | 4,620 0 0.0% | Mkt Cap: 605.3m
- Published:
01 Aug 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
In its recent financial results, Basilea's partner Astellas reported Cresemba (isavuconazole, antifungal) Q2/2019 US sales of $37m, taking H1/2019 US sales to $67m (+26% YoY), slightly above our $65.5m forecast. The company also stated that it projects FY2019E (April 2019 - March 2020) sales to reach $143m, in line with our estimate for Astellas's fiscal year. This increases our confidence in our peak sales forecasts for Cresemba of nearly $230m in the US and $645m globally by 2026E, of which